Centocor Ortho abandons pursuit of US marketing for ovarian cancer drug, for now
This article was originally published in Scrip
Executive Summary
After struggling to appease the US FDA, Centocor Ortho Biotech has thrown in the towel in trying to gain US approval for its investigational ovarian cancer drug trabectedin, at least for the time being.